The Role of Surgery in the Treatment of Metachronous Liver Metastasis from Gastric Cancer: A Systematic Review

被引：9
作者：
Aurello, Paolo [1 ]
Minervini, Andrea [1 ]
Pace, Marco [1 ]
D'angelo, Francesco [1 ]
Nigri, Giuseppe [1 ]
Antolino, Laura [1 ]
Valabrega, Stefano [1 ]
Ramacciato, Giovanni [1 ]
Petrucciani, Niccolo [1 ]
机构：
[1] Sapienza Univ Rome, St Andrea Univ Hosp, Dept Med & Surg Sci & Translat Med, Gen Surg Units, Via Grottarossa 1035-1039, I-00189 Rome, Italy
来源：
ANTICANCER RESEARCH | 2022年 / 42卷 / 01期
关键词：
Gastric cancer; metachronous liver metastasis; liver resection; review; HEPATIC METASTASES; SURGICAL RESECTION; HEPATECTOMY; ADENOCARCINOMA; CHEMOTHERAPY; SURVIVAL; THERAPY; DISEASE;
D O I：
10.21873/anticanres.15453
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: Few data are available regarding metachronous liver metastases from gastric cancer. We aimed to identify data regarding the survival of these patients, considering the chosen treatment, with particular attention to the role of surgery. Materials and Methods: A systematic review was carried out from 2000 to 2020. We chose articles reporting data from patients with metachronous liver metastases after curative gastrectomy. Data regarding 1-, 3and 5-year overall survival were analyzed. Results: Survival was improved in patients eligible for surgery (absence of extrahepatic non-curative factors and feasible complete macroscopic removal of liver deposits, i.e., H1 and H2 liver involvement, metastases less than 5 cm in size) when curative liver resection was performed, with a median overall survival of 24 months (vs. 3.13 in patients treated with chemotherapy). N Status, extent and maximum size of liver metastases, and hepatic surgical treatment were identified as independent prognostic factors. Conclusion: Selected patients with metachronous liver metastases from gastric cancer may benefit from multimodal 'aggressive' treatment. When hepatic involvement is limited (H1 and H2) and the size of metastases less than 5 cm, surgery was shown to increase survival.
引用
收藏
页码：25 / 33
页数：9
相关论文
共 36 条
[1]   Gastric cancer deaths by age group in Japan: Outlook on preventive measures for elderly adults [J].
Asaka, Masahiro ;
Kobayashi, Masanobu ;
Kudo, Takahiko ;
Akino, Kozo ;
Asaka, Yuichiro ;
Fujimori, Kenji ;
Kikuchi, Shogo ;
Kawai, Sayo ;
Kato, Mototsugu .
CANCER SCIENCE, 2020, 111 (10) :3845-3853
[2]   Hepatic Resection for Hepatic Metastases from Gastric Adenocarcinoma [J].
Baek, Hyoung-Un ;
Kim, Sang Bum ;
Cho, Eung-Ho ;
Jin, Sung-Ho ;
Yu, Hang Jong ;
Lee, Jong-Inn ;
Bang, Ho-Yoon ;
Lim, Chang-Sup .
JOURNAL OF GASTRIC CANCER, 2013, 13 (02) :86-92
[3]  
Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]
[4]   XELOX (capecitabine plus oxaliplatin):: Active first-line therapy for patients with metastatic colorectal cancer [J].
Cassidy, J ;
Tabernero, J ;
Twelves, C ;
Brunet, R ;
Butts, C ;
Conroy, T ;
Debraud, F ;
Figer, A ;
Grossmann, J ;
Sawada, N ;
Schöffski, P ;
Sobrero, A ;
Van Cutsem, E ;
Diaz-Rubio, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2084-2091
[5]   Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? [J].
Creasy, John M. ;
Sadot, Eran ;
Koerkamp, Bas Groot ;
Chou, Joanne F. ;
Gonen, Mithat ;
Kemeny, Nancy E. ;
Balachandran, Vinod P. ;
Kingham, T. Peter ;
DeMatteo, Ronald P. ;
Allen, Peter J. ;
Blumgart, Leslie H. ;
Jarnagin, William R. ;
D'Angelica, Michael I. .
SURGERY, 2018, 163 (06) :1238-1244
[6]   Hepatectomy for Liver Metastasis of Gastric Cancer: A Meta-Analysis [J].
Cui, Jun-Kai ;
Liu, Mei ;
Shang, Xiao-Ke .
SURGICAL INNOVATION, 2019, 26 (06) :692-697
[7]  
FEGIZ G, 1991, INT SURG, V76, P58
[8]   Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 [J].
Ferlay, J. ;
Colombet, M. ;
Soerjomataram, I. ;
Dyba, T. ;
Randi, G. ;
Bettio, M. ;
Gavin, A. ;
Visser, O. ;
Bray, F. .
EUROPEAN JOURNAL OF CANCER, 2018, 103 :356-387
[9]   Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial [J].
Fujitani, Kazumasa ;
Yang, Han-Kwang ;
Mizusawa, Junki ;
Kim, Young-Woo ;
Terashima, Masanori ;
Han, Sang-Uk ;
Iwasaki, Yoshiaki ;
Hyung, Woo Jin ;
Takagane, Akinori ;
Park, Do Joong ;
Yoshikawa, Takaki ;
Hahn, Seokyung ;
Nakamura, Kenichi ;
Park, Cho Hyun ;
Kurokawa, Yukinori ;
Bang, Yung-Jue ;
Park, Byung Joo ;
Sasako, Mitsuru ;
Tsujinaka, Toshimasa .
LANCET ONCOLOGY, 2016, 17 (03) :309-318
[10]   Prognostic Significance of Conversion Surgery Following Firstor Second-line Chemotherapy for Unresectable Gastric Cancer [J].
Fukuchi, Minoru ;
Mochiki, Erito ;
Ishiguro, Toru ;
Kumagai, Youichi ;
Ishibashi, Keiichiro ;
Ishida, Hideyuki .
ANTICANCER RESEARCH, 2018, 38 (11) :6473-6478
1234